Caitong International Asset Management Co. Ltd Has $927,000 Holdings in Altimmune, Inc. $ALT

Caitong International Asset Management Co. Ltd raised its stake in Altimmune, Inc. (NASDAQ:ALT) by 25,474.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 239,630 shares of the company’s stock after acquiring an additional 238,693 shares during the quarter. Altimmune comprises approximately 0.7% of Caitong International Asset Management Co. Ltd’s investment portfolio, making the stock its 27th biggest holding. Caitong International Asset Management Co. Ltd owned approximately 0.30% of Altimmune worth $927,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ALT. GAMMA Investing LLC grew its position in shares of Altimmune by 214.2% during the 1st quarter. GAMMA Investing LLC now owns 6,745 shares of the company’s stock worth $34,000 after buying an additional 4,598 shares during the period. PFG Investments LLC lifted its stake in Altimmune by 31.6% in the first quarter. PFG Investments LLC now owns 17,500 shares of the company’s stock valued at $88,000 after buying an additional 4,200 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Altimmune by 1.2% in the first quarter. Bank of New York Mellon Corp now owns 189,000 shares of the company’s stock valued at $945,000 after buying an additional 2,162 shares in the last quarter. Concurrent Investment Advisors LLC acquired a new stake in shares of Altimmune in the first quarter valued at approximately $108,000. Finally, Brown Wealth Management LLC raised its holdings in shares of Altimmune by 100.0% in the first quarter. Brown Wealth Management LLC now owns 100,024 shares of the company’s stock valued at $500,000 after purchasing an additional 50,024 shares during the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Trading Up 1.5%

ALT opened at $3.96 on Friday. Altimmune, Inc. has a twelve month low of $2.90 and a twelve month high of $11.16. The company has a 50-day simple moving average of $3.79 and a 200 day simple moving average of $4.56. The company has a quick ratio of 20.44, a current ratio of 20.44 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $349.51 million, a price-to-earnings ratio of -3.36 and a beta of 0.07.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.05. Altimmune had a negative net margin of 438,730.03% and a negative return on equity of 62.63%. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. Analysts predict that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on ALT shares. JMP Securities lowered their price objective on shares of Altimmune from $25.00 to $15.00 and set a “market outperform” rating on the stock in a report on Thursday, July 10th. The Goldman Sachs Group upgraded shares of Altimmune to a “strong sell” rating in a report on Thursday, July 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research note on Wednesday, October 8th. William Blair restated a “market perform” rating on shares of Altimmune in a research note on Friday, June 27th. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Monday. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $17.40.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.